Patient-reported outcomes for the phase 3 FURLONG study of furmonertinib versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer
一项针对局部晚期或转移性EGFR突变阳性非小细胞肺癌患者的FURLONG III期研究的患者报告结局，该研究比较了呋莫替尼与吉非替尼作为一线治疗方案的疗效。
期刊:The Lancet Regional Health Western Pacific
影响因子:8.1
doi:10.1016/j.lanwpc.2024.101122
Shi, Yuankai; Chen, Gongyan; Wang, Xiang; Liu, Yunpeng; Wu, Lin; Hao, Yanrong; Liu, Chunling; Zhu, Shuyang; Zhang, Xiaodong; Li, Yuping; Liu, Jiwei; Cao, Lejie; Cheng, Ying; Zhao, Hui; Zhang, Shucai; Zang, Aimin; Cui, Jiuwei; Feng, Jian; Yang, Nong; Hu, Jie; Liu, Fei; Jiang, Yong; Ge, Nan
